Form 10-Q NovoCure Ltd For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
NovoCure Ltd. (NVCR) PT Raised to $24 at H.C. Wainwright
July 26, 2024 6:48 AM EDTH.C. Wainwright analyst Emily Bodnar raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $24.00 (from $22.00) while maintaining a Neutral rating.
The analyst comments "Optune growth in glioblastoma (GBM) fueled by impressive France launch; additional launches could occur in 2025. Novocure announced 2Q24 financial results and provided a corporate update on July 25. Sales in 2Q24 were $150.4M, roughly an 8.6% increase from 1Q24. We note that 1Q24 revenues... More



